Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan
2013 · International Journal of Clinical Oncology · 27 citations
https://doi.org/10.1007/s10147-013-0643-5
H
Hiroyasu Yamashiro
Tenri Hospital(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
77
Papers
1.8K
Citations
18
h-index
22
i10-index
Hiroyasu Yamashiro is an academic researcher from Tenri Hospital. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 18, co-authored 66 publications.
ORCID: 0000-0003-1778-6735Papers by this author
worksPhase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
2022 · Scientific Reports · 17 citations
https://doi.org/10.1038/s41598-022-27048-3
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study
2020 · Breast Cancer · 10 citations
https://doi.org/10.1007/s12282-020-01138-4
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01
2020 · Breast Cancer · 8 citations
https://doi.org/10.1007/s12282-020-01057-4
[Herceptin (trastuzumab)].
2007 · PubMed · 8 citations
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
2022 · Breast Cancer · 3 citations
https://doi.org/10.1007/s12282-022-01399-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat